Evaluating Liposomal Bupivacaine Versus Conventional Bupivacaine for Nerve Block to Improve Recovery After Thoracoscopic Lung Surgery

What this Trial Is About

This research aims to evaluate the effect of preoperative intercostal nerve block ICNB using liposomal bupivacaine compared to conventional bupivacaine hydrochloride on the quality of recovery after video-assisted thoracoscopic surgery VATS for partial pneumonectomy. VATS is a less invasive lung surgery technique, but managing postoperative pain remains a challenge. Liposomal bupivacaine is designed to provide longer-lasting pain relief, potentially improving recovery quality by reducing pain and opioid use after surgery. Participants receive a single-dose ICNB under thoracoscopy before surgery. One group gets 30 mL of 0.25% bupivacaine hydrochloride injected into six intercostal spaces, while the other group receives a 30 mL diluted solution of bupivacaine liposome similarly administered. This study compares these two nerve block methods to assess their impact on recovery. During the study, participants recovery quality is assessed primarily by the Quality of Recovery-15 QoR-15 score at 24 hours post-surgery, with additional measures at 48 hours. Other evaluations include pain scores, opioid consumption, patient satisfaction, and recovery times in the post-anesthesia care unit. The study follows participants until 48 hours after surgery to monitor these outcomes.

Effect of Intercostal Nerve Block With Liposomal Bupivacaine on Quality of Recovery in VATS Partial Pneumonectomy